Efficacy of lenvatinib plus pembrolizumab for recurrent endometrial cancer: a focus on the nonendometrioid histology including carcinosarcoma
LP therapy demonstrated clinical activity in nonendometrioid carcinoma, including rare subtypes such as carcinosarcoma and mesonephric-like adenocarcinoma. Further accumulation of patients is warranted to validate its efficacy in these uncommon histologic types.
Authors
- Yuji Takei (ORCID: https://orcid.org/0000-0002-1744-5570)
- Yoshifumi Takahashi (ORCID: https://orcid.org/0000-0003-3319-1205)
- Miku Takadera
- Akiyo Taneichi
- Takahiro Koyanagi
- Hiroyuki Fujiwara
- Yasushi Saga
Institutions
- Jichi Medical University (JP)
Publication Details
- Journal
- Japanese Journal of Clinical Oncology
- Published
- 2026-02-16
- DOI
- https://doi.org/10.1093/jjco/hyag036
- Primary Topic
- Endometrial and Cervical Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00